Abstract
Introduction: Alzheimer’s disease (AD) is a progressive, neurodegenerative disease that
severely affects individuals' cognitive abilities, memory, and quality of life. It affects the elderly population,
and there is no permanent prevention or cures available to date, treatments mainly aiming to alleviate
the symptoms as and when they appear. Alternate therapeutic approaches are being researched
constantly, and there is a growing focus on phytomedicine, herbal medicine, organic compounds, and
ayurvedic compounds for the treatment of AD.
Methods: The current study aims to provide an extensive review of these plants against AD from the
currently existing literature. Most relevant keywords like Alzheimer’s Disease, phytomedicines, ethnic
medicines, the role of phytomedicine in neuroprotection, common phytomedicines against AD, etc.,
were used to select the plants and their metabolites effective in treating AD. The study focuses on six
plants: Panax ginseng, Ginkgo biloba, Bacopa monnieri, Withania somnifera, Curcuma longa, and Lavandula
angustifolia. Their active components have been studied along with neuroprotective properties,
and evidence of in-vitro, pre-clinical, and clinical studies conducted to prove their therapeutic potential
against the disease have been presented.
Results: All plants envisaged in the study show potential for fighting against AD to varying degrees.
Their compounds have shown therapeutic effects by reversing the neurological changes such as clearing
Aβ plaque and neurofibrillary tangle formation, and ameliorative effects against neurodegeneration
through processes including improving concentration, memory, cognition and learning, higher working
and cue memory, improved spatial memory, inhibition of NF-κB expression, inhibiting the release of
pro-inflammatory cytokines, inhibition of AChE and lipid peroxidase enzymes, and reduction of interleukin
levels and tumor necrosis factor-alpha.
Conclusion: The present review is a comprehensive and up-to-date analysis supported by the evidentiary
proofs from pre-clinical studies, meta-analyses, and review papers related to natural phytochemicals'
impact on neurodegenerative disorders like AD.
Keywords:
Alzheimer’s disease, phytomedicines, neuroprotection by phytomedicines, neuroprotective phytoconstituents, Panax ginseng, Ginkgo biloba, Bacopa monnieri, Withania somnifera, Curcuma longa, Lavandula angustifolia.
[1]
Upadhyaya P, Seth V, Ahmad M. Therapy of Alzheimer’s disease: An update. Afr J Pharm Pharmacol 2010; 4(6): 408-21.
[2]
Lane CA, Hardy J, Schott JM. Alzheimer’s disease. Eur J Neurol 2018; 25(10): 59-70.
[15]
Obulesu M, Rao DM. Effect of plant extracts on Alzheimer’s disease: An insight into therapeutic avenues. J Neurosci Rural Practice 2011; 2: 56-61.
[16]
Howes MJR, Perry NSL, Houghton PJ. Plants with traditional uses and activities, relevant to the management of Alzheimer’s disease and other cognitive disorders. Phytother Res 2003; 17: 1-18.
[35]
Brondino N, De Silvestri A, Re S, et al. A systematic review and meta-analysis of Ginkgo biloba in neuropsychiatric disorders: From ancient tradition to modern-day medicine. Evid-Based Complement Altern Med 2013; 2013: 1-11.
[41]
Singh SK, Srivastav S, Castellani RJ, Plascencia-Villa G, Perry G. Neuroprotective and antioxidant effect of Ginkgo biloba extract against AD and other neurological disorders. Neurotherapeutics 2019; 16: 666-74.
[49]
Stough C, Silberstein RB, Pipingas A, Song J, Camfield DA, Nathan PJ. Examining brain-cognition effects of Ginkgo biloba extract: Brain activation in the left temporal and left prefrontal cortex in an object working memory task. Evidence-based Complement Altern Med 2011.
[65]
Ahirwar S, Tembhre M, Gour S, Namdeo A. Anticholinesterase efficacy of Bacopa monnieri against the brain regions of rat - a novel approach to therapy for Alzheimer ’ s disease. Asian J Exp Sci 2012; 26(1): 65-70.
[67]
Goswami S, Saoji A, Kumar N, Thawani V, Tiwari M, Thawani M. Effect of Bacopa monnieri on cognitive functions in Alzheimer’s disease patients. Int J Collab Res Intern Med Public Health 2011; 3(4): 285-93.
[69]
Singh G, Sharma PK, Dudhe R, Singh S. Biological activities of Withania somnifera. Ann Biol Res 2010; 1(3): 56-63.
[70]
Gupta G, Rana A. PHCOG MAG.: Plant review Withania somnifera (Ashwagandha): A review. Withania somnifera 2007; 1(1): 129-36.
[74]
Zahiruddin S, Basist P, Parveen A, et al. Ashwagandha in brain disorders: A review of recent developments. J Ethnopharmacol 2020; 2020: 112876.
[75]
Das TK, Hamid MRWA, Das TK, Shad KF. Potential of glycowithanolides from Withania somnifera (Ashwagandha) as therapeutic agents for the treatment of Alzheimer’s disease. World J Pharm Res 2015; 4(6): 16-38.
[78]
Dar NJ, Ahmad M. Neurodegenerative diseases and Withania somnifera (L.): An update. J Ethnopharmacol 2020; 256: 112769.
[84]
Tohda C, Nagasaka K, Fukuda H, Hashimoto M, Ebe Y. Scientific basis for the anti dementia drugs of constituents from Ashwagandha (Withania somnifera). Med Pharm Soc Wakan-Yaku 2007; 24: 87-9.
[89]
Mishra S, Palanivelu K. The effect of curcumin (turmeric) on Alzheimer’s disease: An overview. Ann Indian Acad Neurol 2008; 11(1): 13-9.
[92]
Reddy PH, Manczak M, Yin X, et al. Protective effects of Indian spice curcumin against Amyloid-ß in Alzheimer’s disease. J Alzheimer's Dis 2018; 61: 843-66.
[106]
Jianu C, Pop G, Gruia AT, Horhat FG. Chemical composition and antimicrobial activity of essential oils of lavender (Lavandula angustifolia) and lavandin (Lavandula x intermedia) grown in Western Romania. Int J Agric Biol 2013; 15(4): 772-6.
[111]
Soheili M, Salami M, Haghir A, Zali H, Tavirani MR. Aqueous extract of Lavandula angustifolia alter protein expression in Alzheimer rats. J Reports Pharm Sci 2014; 3(1): 1-9.